Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 45: 829-837, 1999;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roberts, W. L.
Right arrow Articles by Annesley, T. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roberts, W. L.
Right arrow Articles by Annesley, T. M.
Related Collections
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 1999;45:829-837.)
© 1999 American Association for Clinical Chemistry, Inc.

Articles

Falsely Increased Immunoassay Measurements of Total and Unbound Phenytoin in Critically Ill Uremic Patients Receiving Fosphenytoin

William L. Roberts1,a, Barun K. De2, John P. Coleman2 and Thomas M. Annesley3

1 Department of Pathology, University of Utah Health Science Center, Salt Lake City, UT 84132.

2 Department of Pathology, University of Mississippi Medical Center, Jackson, MS 39216.

3 Department of Pathology, University of Michigan Medical Center, Ann Arbor, MI 48109.
a Address correspondence to this author at: ARUP Laboratories, 500 Chipeta Way, Salt Lake City, UT 84108. Fax 801-584-5207; e-mail william.roberts{at}arup-lab.com

Background: Fosphenytoin, a phosphate ester prodrug of phenytoin, is metabolized to phenytoin in vivo. Phenytoin metabolites accumulate in renal insufficiency and cross-react in some phenytoin immunoassays. Our aim was to determine the accuracy of phenytoin immunoassays in renal patients treated with fosphenytoin.

Methods: We measured phenytoin with HPLC and with the aca, ACS:180, TDx phenytoin II, Vitros, and AxSYM methods. Specimens were collected 2–120 h after fosphenytoin administration from 17 patients with renal insufficiency.

Results: The AxSYM, TDx phenytoin II, ACS:180, and Vitros assays displayed falsely increased phenytoin results up to 20 times higher than the HPLC results. The aca Star results for these specimens were comparable to the HPLC results. Although fosphenytoin can cross-react with phenytoin immunoassays, no fosphenytoin was detected by a sensitive HPLC method in any sample that was tested for its presence.

Conclusion: These results are consistent with the formation of one or more novel metabolites or adducts of fosphenytoin that accumulate in some critically ill patients with renal insufficiency and that display significant cross-reactivity with some, but not all, phenytoin immunoassay methods.© 1999 American Association for Clinical Chemistry




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
M. Oellerich and V. W. Armstrong
Prodrug Metabolites: Implications for Therapeutic Drug Monitoring
Clin. Chem., May 1, 2001; 47(5): 805 - 806.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
T. M. Annesley, S. Kurzyniec, G. D. Nordblom, N. Buchanan, W. Pool, M. Reily, R. Talaat, and W. L. Roberts
Glucuronidation of Prodrug Reactive Site: Isolation and Characterization of Oxymethylglucuronide Metabolite of Fosphenytoin
Clin. Chem., May 1, 2001; 47(5): 910 - 918.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association for Clinical Chemistry.